The Use of Sorafenib in the Thyroid Cancer.
Eur Endocrinol
; 9(1): 28-31, 2013 Mar.
Article
em En
| MEDLINE
| ID: mdl-30349607
ABSTRACT
There are not effective therapies for metastatic unresectable, non-RAI-avid thyroid carcinomas. Fortunately, thyroid carcinomas represent a promising paradigm for targeted therapy due to the presence of activing mutations of genes coding the kinase tyrosines which are involved in all functions of cancer cells (such as growth or invasion). In this paper an efficacy and toxicity of sorafenib, one of the multi-kinase inhibitors in thyroid carcinomas treatment is presented.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Eur Endocrinol
Ano de publicação:
2013
Tipo de documento:
Article